In a report released yesterday, Mark Massaro from Canaccord Genuity maintained a Buy rating on Heska Corp (HSKA), with a price target of $123. The company’s shares closed yesterday at $100.87.
According to TipRanks.com, Massaro is a 5-star analyst with an average return of 16.5% and a 59.0% success rate. Massaro covers the Healthcare sector, focusing on stocks such as HTG Molecular Diagnostics, Quanterix Corporation, and Orasure Technologies.
Currently, the analyst consensus on Heska Corp is a Moderate Buy with an average price target of $131.
See today’s analyst top recommended stocks >>
Heska Corp’s market cap is currently $756.3M and has a P/E ratio of 131. The company has a Price to Book ratio of 6.88.
Based on the recent corporate insider activity of 36 insiders, corporate insider sentiment is negative on the stock. Last month, Nancy Wisnewski, the EVP, Diag. Ops & Prod. Dev. of HSKA bought 5,000 shares for a total of $22,000.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Heska Corp. engages in the provision of veterinary and animal health diagnostic, and specialty products. It operates through the Core Companion Animal Health; and Other Vaccines, and Pharmaceuticals and Products segments.
